<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">Of the 92 approved antiviral drugs, HIV and HCV drugs account for two-thirds of all approvals [
 <xref ref-type="bibr" rid="CR28">28</xref>]. The antiviral landscape is dominated by small molecules which constitute 87% of approved antiviral agents. Despite extensive studies involving host-targets and their relevance in the antiviral life cycle, the number of approved antivirals directed against host proteins has lagged significantly. Only about 10% of all approved antivirals are directed against host-proteins, half of which are interferon-related biologics [
 <xref ref-type="bibr" rid="CR28">28</xref>, 
 <xref ref-type="bibr" rid="CR29">29</xref>] (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>).
</p>
